Tailoring the Radionuclide Encapsulation and Surface Chemistry of La(223Ra)VO4 Nanoparticles for Targeted Alpha Therapy
Open Access
- 23 January 2021
- journal article
- research article
- Published by MDPI AG in Journal of Nanotheranostics
- Vol. 2 (1) , 33-50
Abstract
The development of targeted alpha therapy (TAT) as a viable cancer treatment requires innovative solutions to challenges associated with radionuclide retention to enhance local tumor cytotoxicity and to minimize off-target effects. Nanoparticles (NPs) with high encapsulation and high retention of radionuclides have shown potential in overcoming these issues. This article shows the influence of pH on the structure of lanthanum vanadate (LaVO4) NPs and its impact on the radiochemical yield of 223Ra and subsequent retention of its decay daughters, 211Pb and 211Bi. An acidic pH (4.9) results in a high fraction of La(223Ra)VO4 NPs with tetragonal structure (44.6–66.1%) and a 223Ra radiochemical yield 80% of La(223Ra)VO4 NPs with monoclinic structure and increases the 223Ra radiochemical yield >85%. The leakage of decay daughters from La(223Ra)VO4 NPs (pH 11) was 223Ra)VO4 NPs with carboxylate and phosphate compounds resulted in a threefold decrease in hydrodynamic diameter and a 223Ra radiochemical yield between 74.7% and 99.6%. These results show the importance of tailoring the synthesis parameters and surface chemistry of LaVO4 NPs to obtain high encapsulation and retention of radionuclides.Keywords
Funding Information
- Laboratory Directed Research and Development (LOIS 9361)
This publication has 62 references indexed in Scilit:
- Development of Targeted Alpha Particle Therapy for Solid TumorsMolecules, 2019
- Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide TherapyNeuroendocrinology, 2018
- 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Targeted alpha therapy using Radium-223: From physics to biological effectsCancer Treatment Reviews, 2018
- Antitumor Activity of Novel Bone-seeking, α-emitting 224Ra-solution in a Breast Cancer Skeletal Metastases ModelAnticancer Research, 2018
- Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.Journal of Clinical Oncology, 2018
- 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate CancerJournal of Nuclear Medicine, 2016
- A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?Pharmaceuticals, 2015
- Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90YCancer Research, 2009
- Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome CarriersBioconjugate Chemistry, 2007